Bhaskar Chaudhuri Net Worth

The estimated Net Worth of Bhaskar Chaudhuri is at least $2.18 millió dollars as of 24 June 2024. Bhaskar Chaudhuri owns over 3,350 units of Arcutis Biotherapeutics Inc stock worth over $56,282 and over the last 9 years he sold ARQT stock worth over $1,829,000. In addition, he makes $292,639 as Independent Director at Arcutis Biotherapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Bhaskar Chaudhuri ARQT stock SEC Form 4 insiders trading

Bhaskar has made over 10 trades of the Arcutis Biotherapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 3,350 units of ARQT stock worth $35,242 on 24 June 2024.

The largest trade he's ever made was selling 10,000 units of Arcutis Biotherapeutics Inc stock on 1 June 2021 worth over $275,000. On average, Bhaskar trades about 2,283 units every 56 days since 2015. As of 24 June 2024 he still owns at least 5,350 units of Arcutis Biotherapeutics Inc stock.

You can see the complete history of Bhaskar Chaudhuri stock trades at the bottom of the page.

Bhaskar Chaudhuri biography

Dr. Bhaskar Chaudhuri Ph.D. serves as Independent Director of the Company. Since June 2011, he has been the Operating Partner at Frazier Healthcare Ventures. Prior to that time, Dr. Chaudhuri served as President of Valeant Pharmaceuticals International, Inc. (currently Bausch Health) from January 2009 to September 2010. Prior to joining Valeant, Dr. Chaudhuri served for seven years as President and Chief Executive Officer of Dow Pharmaceutical Sciences, Inc. and as a member of its board of directors from 2003 to 2008, at which time Dow was acquired by Valeant. Prior to that, Dr. Chaudhuri served as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, Inc., a subsidiary of Mylan N.V., from September 2000 to March 2002. Prior to his position at Bertek, Dr. Chaudhuri served as the General Manager of the Dermatology Division of Mylan from September 1998 to August 2000. Dr. Chaudhuri joined Mylan through the acquisition of Penederm, Inc., where he worked from 1992 to 1998 in a number of senior positions before becoming the Vice President of Research and Development. Dr. Chaudhuri serves on the boards of directors of Teligent, Inc., and previously served on the board of directors of Corium International, Inc. He also serves on the Advisory Board of the Johns Hopkins Berman Institute of Bioethics. Dr. Chaudhuri received a B.S. in Pharmacy and a M.S. in Industrial Pharmacy from Jadavpur University and a Ph.D. in Pharmaceutics from the University of Louisiana. Chaudhuri is qualified to serve on our board of directors because of his many years of experience in the pharmaceutical industry, including his prior positions in senior executive roles at major pharmaceutical companies.

What is the salary of Bhaskar Chaudhuri?

As the Independent Director of Arcutis Biotherapeutics Inc, the total compensation of Bhaskar Chaudhuri at Arcutis Biotherapeutics Inc is $292,639. There are 6 executives at Arcutis Biotherapeutics Inc getting paid more, with Todd Watanabe having the highest compensation of $1,140,300.

How old is Bhaskar Chaudhuri?

Bhaskar Chaudhuri is 66, he's been the Independent Director of Arcutis Biotherapeutics Inc since 2016. There are 2 older and 25 younger executives at Arcutis Biotherapeutics Inc. The oldest executive at Arcutis Biotherapeutics Inc is Howard Welgus, 68, who is the Director.

What's Bhaskar Chaudhuri's mailing address?

Bhaskar's mailing address filed with the SEC is C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE, CA, 92618.

Insiders trading at Arcutis Biotherapeutics Inc

Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron és Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.

What does Arcutis Biotherapeutics Inc do?

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.

Complete history of Bhaskar Chaudhuri stock trades at Teligent Inc, Arcutis Biotherapeutics Inc és Tarsus Pharmaceuticals

Arcutis Biotherapeutics Inc executives and stock owners

Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include:

• Todd Watanabe,
  President, Chief Executive Officer, Director
• Kenneth Lock,
  Chief Commercial Officer
• Todd Franklin Watanabe M.A.,
  Pres, CEO & Director
• Patricia Turney,
  Senior Vice President - Manufacturing
• Dr. Patrick E. Burnett M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Kenneth A. Lock,
  Chief Commercial Officer
• Bhaskar Chaudhuri,
  Independent Director
• Joseph Turner,
  Independent Director
• Ricky Sun,
  Independent Director
• Jonathan Silverstein,
  Independent Director
• Howard Welgus,
  Director
• Halley Gilbert,
  Director
• Terrie Curran,
  Director
• Patrick Burnett,
  Chief Medical Officer
• Keith Klein,
  General Counsel
• Frank Pompilio,
  Vice President - Medical Affairs
• Lynn Navale,
  Vice President - Biometrics
• Charlotte Merritt,
  Vice President - Regulatory Affairs
• Ayisha Jeter,
  Vice President of Market Access
• Meg Elias,
  Vice President - Clinical Operations
• Bethany Dudek,
  Vice President - Quality
• David Berk,
  Vice President - Clinical Development
• Heather Armstrong,
  Vice President of Investor Relations and Corporate Communications
• Kimberly Lathroum,
  Vice President of Marketing
• Jay Ramsinghani,
  Vice President of Commercial Strategy and Operations
• Scott Burrows,
  Vice President - Finance
• John Smither,
  Chief Financial Officer
• David Osborne,
  Co-Founder, Chief Technical Officer
• Patrick Heron,
  Independent Chairman of the Board
• Masaru Matsuda Esq., J.D.,
  Gen. Counsel & Corp. Sec.
• Courtney Barton,
  Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer
• Eric McIntyre,
  Head of Investor Relations
• Dr. David W. Osborne,
  Chief Technical Officer
• Patricia A. Turney,
  Sr. VP of Operations
• Scott L. Burrows,
  CFO & Principal Accounting Officer
• Larry Todd Edwards,
  SVP Chief Commercial Officer
• Daniel Estes,
  Director
• Neha Krishnamohan,
  Director
• David Joseph Topper,
  Chief Financial Officer
• Masaru Matsuda,
  See Remarks
• Capital Life Sciences Inves...,
  
• Advisors Llcorbimed Capital...,
  
• Life Sciences Viii, L.P.Fhm...,
  
• Matthew Richard Moore,
  SVP and Chief Business Officer
• Life Sciences Viii, L.P.Fhm...,
  
• Sue Jean Lin,
  Director
• Keith R Leonard,
  Director
• Life Sciences Viii, L.P.Fhm...,